Trial · NCT07309380
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
NCT07309380, Phase 3, Not yet recruiting, Shanghai HEP Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D. Trials, record NCT07309380. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07309380
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
- NCT number
- NCT07309380
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.
- Conditions
- Hepatitis D, Chronic
- Interventions
- Hepalatide 2.1mg, Placebo of Hepalatide
- First posted
- 2025-12-30
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of subjects who achieved response | 48 weeks of treatment | HDV RNA suppression (\< LLOQ) or a decrease of ≥ 2 log10 from baseline combined with ALT normalization |
| Secondary | Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline | 48 weeks of treatment | |
| Secondary | Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline and normalized ALT | Continuous treatment for 48 weeks | |
| Secondary | Proportion of subjects with HDV RNA below the limit of detection (LOD) | Continuous treatment for 48 weeks | |
| Secondary | Changes in HDV RNA relative to baseline | Continuous treatment for 48 weeks | |
| Secondary | Proportion of subjects with normalized ALT | Continuous treatment for 48 weeks | |
| Secondary | Changes in ALT relative to baseline | Continuous treatment for 48 weeks | |
| Secondary | Changes in HBV-related parameters (HBV DNA, HBeAg, qHBsAg, etc.) | Continuous treatment for 48 weeks | |
| Secondary | Changes in histological response of the liver | Continuous treatment for 48 weeks | |
| Secondary | Change in Model for End-Stage Liver Disease (MELD) score | Continuous treatment for 48 weeks |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07309380
GET https://conductscience.org/api/trials/v1/NCT07309380/registered